Semax

Semax is a synthetic heptapeptide developed in the Soviet Union and Russia beginning in the 1980s, built from the first four amino acids of the adrenocorticotropic hormone fragment ACTH(4-10) fused to a Pro-Gly-Pro tripeptide tag, giving it the chemical name ACTH(4-7)-Pro-Gly-Pro. The design rationale was to separate the classical hormonal, cortisol-raising activity of ACTH, which resides in the portion of the molecule that Semax lacks, from a separate trophic, brain-protective activity attributed to the retained N-terminal fragment. Since 1994, Semax has been a registered prescription drug in Russia, sold as an intranasal solution in two strengths, a 0.1 percent formulation for cognitive and memory complaints and a 1 percent formulation for acute conditions including ischemic stroke recovery and optic nerve disease. This registered status places Semax among a small number of peptides in this queue with a genuine, decades-long domestic regulatory history, though no Western regulatory agency, including the FDA or European Medicines Agency, has evaluated or approved it for any indication, and outside Russia it exists only as an unregulated research chemical typically purchased as nasal drops or spray.

The best-supported mechanism, replicated across a series of rat studies from the Dolotov research group between 2001 and 2010, is direct upregulation of brain-derived neurotrophic factor (BDNF) protein and messenger RNA, along with its receptor TrkB, in the hippocampus and basal forebrain following Semax administration. A related and less consistently replicated body of work reports induction of nerve growth factor (NGF) and other neurotrophins in rat glial cell culture and rat brain tissue. A separate line of in vitro evidence found that Semax inhibits enkephalin-degrading aminopeptidases in human serum, suggesting a possible secondary mechanism involving potentiation of endogenous opioid peptide signaling, though whether this biochemical finding translates into a meaningful central effect after intranasal dosing has not been established. Semax degrades rapidly once administered, chiefly into the tripeptide Pro-Gly-Pro, which itself shows independent biological activity in some rodent studies, so the net pharmacological effect of dosing intact Semax likely reflects a combination of parent-peptide and metabolite activity rather than the intact heptapeptide acting alone.

The strongest evidence tying this rodent mechanism to human outcomes comes from a 110-patient Russian study of post-stroke rehabilitation, which found that Semax (6,000 micrograms per day intranasally) raised plasma BDNF levels and was associated with better recovery on the Barthel index and a standard motor strength scale, particularly when combined with early rehabilitation. This is a real, human, disease-relevant finding, and it distinguishes Semax from most research-only peptides in this queue that rest entirely on animal data. It is also, however, a study design gap worth stating plainly: the trial compared semax-treated and untreated subgroups without randomization, blinding, or a placebo arm, which is a materially weaker design than the placebo-controlled randomized trials that support the small number of FDA-approved peptides elsewhere in this queue. Two older, smaller Russian ophthalmology studies reporting benefit in optic nerve disease and glaucomatous optic neuropathy share the same design limitations and additionally predate modern trial reporting standards. A 2007 hypothesis paper proposing Semax as a candidate for attention-deficit hyperactivity disorder and Rett syndrome is a theoretical proposal based on animal data, not a clinical trial, and no completed controlled human trial in either condition has been published.

Practically, Semax is used exclusively by the intranasal route, since it is not orally bioavailable and no injectable formulation is in clinical use; a rat radiotracer study found that only a small fraction of an intranasally administered dose, on the order of 0.1 percent, actually reaches brain tissue within minutes of dosing, with the majority of the peripherally absorbed peptide degrading rapidly in blood and tissue. Reported side effects in Russian clinical use are generally mild, dominated by local nasal irritation and occasional stimulant-like effects such as irritability or sleep disruption when dosed later in the day, without a well-documented pattern of serious systemic toxicity in the published literature. Within Russia, Semax is manufactured and prescribed as a regulated pharmaceutical; outside Russia, it is sold under the same name by research-chemical vendors without pharmaceutical manufacturing oversight, and that unregulated product should not be assumed equivalent in purity, potency, or safety to the registered Russian drug used in the clinical studies described here.

Mechanism of Action

Structure and the Separation of Trophic from Hormonal Activity

Semax is built from the first four amino acids of the ACTH(4-10) fragment of adrenocorticotropic hormone, Met-Glu-His-Phe, fused to a Pro-Gly-Pro tripeptide, giving the full chemical designation ACTH(4-7)-Pro-Gly-Pro. Native ACTH(4-10) itself lacks the classical adrenal-stimulating activity of full-length ACTH but retains what Russian researchers in the 1970s and 1980s characterized as a separate, receptor-mediated trophic activity relevant to learning and neuroprotection. Semax was designed to preserve this trophic fragment while adding a Pro-Gly-Pro tag intended to slow degradation relative to the unmodified ACTH(4-10) fragment, though as described below, Semax still degrades rapidly once administered.

BDNF and TrkB Upregulation

The most consistently replicated mechanism across the Semax literature is direct upregulation of brain-derived neurotrophic factor. In a pair of companion rat studies published in 2006, Semax administration increased BDNF protein levels in the basal forebrain and increased both BDNF and its receptor TrkB in the hippocampus. Because BDNF-TrkB signaling is central to synaptic plasticity and the molecular processes underlying learning and memory consolidation, this mechanism is the primary basis offered for Semax reported nootropic and neuroprotective effects. The finding has been reproduced across several studies from the same research group over roughly a decade, though independent replication by unrelated laboratories, and direct demonstration of the same mechanism in human brain tissue, remain limited.

Broader Neurotrophin Induction

Beyond BDNF, Semax has been shown to rapidly induce nerve growth factor and other neurotrophin messenger RNAs in rat glial cell cultures, and subsequent in vivo work confirmed neurotrophin gene induction in intact rat brain tissue. This broader neurotrophin-induction profile suggests Semax mechanism is not limited to a single growth factor but instead reflects a more general activation of neurotrophic gene programs, a pattern also seen in the ischemia-focused transcriptome and proteome studies described below.

Neuroprotective Transcriptional Response to Cerebral Ischemia

In rat models of cerebral ischemia-reperfusion, used as an experimental proxy for stroke, Semax treatment shifts brain-wide gene and protein expression toward a neuroprotective profile: reduced pro-inflammatory and pro-apoptotic signaling alongside increased transcription of neurotrophin genes and their receptors in the affected brain tissue. Genome-wide transcriptome sequencing and follow-up proteomic analysis, both published between 2020 and 2021, confirmed this pattern using contemporary molecular methods, updating and extending earlier, more targeted gene-expression findings from 2010. This body of rodent evidence provides the mechanistic rationale for using Semax in Russian stroke rehabilitation protocols, though it remains animal tissue data rather than a direct measurement of the same molecular events in human stroke patients.

Enkephalinase Inhibition and the Pro-Gly-Pro Metabolite

A separate line of in vitro evidence found that Semax inhibits enkephalin-degrading aminopeptidases in human serum, a finding shared with the related Russian peptide Selank, suggesting a possible secondary mechanism involving potentiation of endogenous opioid peptide signaling. Whether this cell-free biochemical finding is physiologically relevant to Semax central nervous system effects after intranasal dosing in a living organism has not been directly established. Complicating mechanistic interpretation further, Semax degrades rapidly in blood and tissue into the tripeptide Pro-Gly-Pro, and at least one rat ischemia study found that Pro-Gly-Pro independently activates neurotrophin gene transcription, meaning the effects attributed to “Semax” in a given study may reflect a combination of intact-peptide and metabolite activity rather than the parent heptapeptide acting alone.

Clinical Evidence

Ischemic Stroke Recovery (Human)

The largest and most disease-relevant human study of Semax followed 110 patients recovering from ischemic stroke, divided into early-rehabilitation (starting at a mean of 89 days post-stroke) and late-rehabilitation (starting at a mean of 214 days post-stroke) cohorts, each further divided into semax-treated and untreated subgroups. Semax was given intranasally at 6,000 micrograms per day across two 10-day courses separated by a 20-day interval. Semax-treated patients showed higher plasma BDNF levels regardless of rehabilitation timing, and the combination of semax with early rehabilitation was associated with the greatest improvement in motor scale scores and Barthel index functional recovery. This is a genuine, disease-relevant human finding rather than an animal or in vitro result, and it is the strongest piece of clinical evidence behind Semax registered Russian indication for stroke recovery. It is equally important to state plainly that this study was not randomized, not blinded, and did not include a placebo arm, comparing instead treated and untreated subgroups within each rehabilitation-timing cohort, a design that leaves open the possibility that unmeasured differences between the groups, rather than semax itself, contributed to the observed differences.

Optic Nerve Disease and Glaucomatous Optic Neuropathy (Human, Older Studies)

Two small Russian ophthalmology studies from around 2000 reported that adding intranasal Semax to standard neuroprotective and anti-inflammatory therapy improved visual function measures in patients with vascular, toxic, or inflammatory optic nerve disease and in glaucomatous optic neuropathy with normalized eye pressure. These findings extend Semax proposed neurotrophic mechanism to the optic nerve, a tissue with substantial energy and trophic-factor demands similar to central nervous system neurons. Both studies are small, decades old, and predate the trial design and reporting standards expected of a modern controlled clinical trial, so they should be read as early, suggestive findings rather than confirmatory evidence of benefit in optic nerve disease.

Attention-Deficit Hyperactivity Disorder: A Theoretical Proposal, Not Trial Evidence

A 2007 hypothesis paper proposed Semax as a theoretically plausible treatment candidate for attention-deficit hyperactivity disorder and for Rett syndrome, reasoning from Semax dopamine-potentiating and BDNF-inducing actions demonstrated in animal studies. This paper is explicitly a hypothesis and opinion article published in a venue dedicated to that format, not a clinical trial, case series, or any form of human outcome data. No completed, published, controlled human trial of Semax in either attention-deficit hyperactivity disorder or Rett syndrome exists as of this writing. This distinction matters because Semax is sometimes marketed for attention and focus using language that implies clinical validation this literature does not provide.

Human Evidence Gap and Design Limitations

Semax occupies an unusual position among the peptides in this queue: it has more human clinical data, spanning stroke recovery and ophthalmology, than most research-only peptides, and it carries a genuine, decades-long drug registration in Russia. At the same time, none of its human studies meet the randomized, double-blind, placebo-controlled standard used to evaluate most Western pharmaceuticals, including the small number of other peptides in this queue that carry an FDA approval. The largest and most rigorous of these studies, the 110-patient post-stroke trial, compared treated and untreated subgroups without randomization or blinding, and the ophthalmology studies are older and smaller still. Readers should treat Semax evidence tier as intermediate: substantially more human data than a purely preclinical research peptide, but well short of the controlled trial evidence that would be required for regulatory approval outside Russia.

Safety and Tolerability

Reported side effects in Russian clinical use of Semax are generally mild and dominated by local nasal irritation or discomfort at the site of intranasal administration. Mild stimulant-like effects, including irritability or sleep disruption when dosed later in the day, have been reported, consistent with Semax nootropic and dopamine-potentiating profile in animal studies. Headache has been reported occasionally in clinical use. No well-documented pattern of serious systemic toxicity has emerged across the published Russian clinical literature, though the adverse-event reporting standards in these older studies fall short of a modern Western regulatory trial, meaning rare or long-term effects could be under-detected.

Regulatory Status

Semax has been a registered prescription drug in Russia since 1994, available in 0.1 percent (cognitive and memory complaints) and 1 percent (acute conditions including ischemic stroke and optic nerve disease) intranasal formulations. This constitutes a genuine, longstanding domestic drug approval, distinguishing Semax from purely research-only peptides elsewhere in this queue. No Western regulatory agency, including the FDA or European Medicines Agency, has evaluated or approved Semax for any indication, and it has no approved use anywhere outside Russia and a small number of other post-Soviet states where it is also registered. Outside that registered market, Semax is sold as an unregulated research chemical, typically marketed for cognitive enhancement, without pharmaceutical manufacturing oversight, quality control, or verified potency. It is not listed by the World Anti-Doping Agency as a specifically prohibited substance in the way growth-hormone-axis peptides are, but this reflects its mechanism and regulatory obscurity outside Russia rather than a specific safety clearance for unsupervised use.

Dosing Guidance

Within its registered Russian indications, Semax is dosed intranasally, with 0.1 percent solution used for cognitive and memory complaints and 1 percent solution used for acute conditions including ischemic stroke, most commonly totaling around 6,000 micrograms per day divided across multiple daily applications. The largest human stroke study used a defined-course regimen, two 10-day courses of 6,000 micrograms per day separated by a 20-day interval, rather than continuous indefinite dosing. No oral formulation exists, since gastrointestinal degradation would eliminate the peptide before absorption, and intranasal administration is the only clinically studied and registered route; reported subcutaneous or injectable use in research-chemical communities is not the studied or registered route and should not be treated as clinically validated. Doses and regimens described here reflect Russian registered prescribing practice and the cited clinical studies, not a protocol independently validated by a Western regulatory trial.